Role of phospholipase A2 in prostate cancer

Binil Eldhose, Claire Wilson

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


Prostate cancer remains one of the leading causes of death in men. Novel therapeutic approaches are necessary to enhance overall outcomes and survival due to the rise of castration-resistant prostate cancer (CRPC) and insensitivity to androgen-deprivation therapies. Men with hormone-refractory prostate cancer are not responding well to current treatments, which emphasizes the significance of finding the molecular factors that contribute to prostate cancer growth and survival that may be employed as therapeutic targets. Compared to existing chemotherapy regimens, such targeted therapies have the potential to considerably reduce toxicity while improving cancer progression. The discovery that prostate cancer cells contain phospholipase A2 (PLA2) and the demonstration that PLA2 inhibition can limit cancer cell proliferation in vitro and in vivo make PLA2 a promising therapeutic target.

Original languageEnglish
Title of host publicationPhospholipases in Physiology and Pathology
Subtitle of host publicationVolumes 1-7
ISBN (Electronic)9780323956871
ISBN (Print)9780323956888
StatePublished - 1 Jan 2023
Externally publishedYes


  • Androgen receptor
  • Arachidonic acid
  • Biomarker
  • ERG
  • Glycerophospholipids
  • Lysophospholipids
  • Metastatic prostate cancer
  • Phospholipase A
  • Prostate cancer
  • Prostate specific antigen


Dive into the research topics of 'Role of phospholipase A2 in prostate cancer'. Together they form a unique fingerprint.

Cite this